Company signals · Biotech & Pharma
Bota Biosciences
1 signal in the current window, with MitchelLake's leadership read on each.
Market context: Against a Talent Market Index of 113.7 (Hot) (up 13.7 month-on-month), Americas is at easing (-3pts) on signal share.
Bota Biosciences: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 22 tracked companies; 0.1% of MitchelLake's Americas signal flow.
Signals at Bota Biosciences
MitchelLake in this thematic
More signals across Biotech & Pharma
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Boehringer Ingelheim →Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Ma Activity · Americas
Biogen →Biogen agreed to acquire RayThera Inc., adding multiple immunology assets including a lead asset entering Phase 1 clinical development.
Intelligence powered by Autonodal ↗